BioTelemetry Company Profile (NASDAQ:BEAT)

About BioTelemetry

BioTelemetry, Inc. (BioTelemetry), formerly CardioNet, Inc., provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment's principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Company's research services focuses on providing cardiac safety monitoring services for drug and medical treatment trials in a research environment. In August 2012, the Company completed the acquisition of Cardiocore Lab, Inc. (Cardiocore).

Industry, Sector and Symbol:

Sector: Medical
Industry: Medical Laboratories & Research
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: BEAT
CUSIP:

Key Metrics:

Previous Close: $18.72
50 Day Moving Average: $19.42
200 Day Moving Average: $16.26
52-Week Range: $8.74 - $21.42
Trailing P/E Ratio: 39.53
Foreward P/E Ratio: 22.12
P/E Growth: 0.00
Market Cap: $520.70M
Outstanding Shares: 28,025,000
Beta: 0.81

Profitability:

Net Margins: 7.11%
Return on Equity: 25.36%
Return on Assets: 15.10%

Debt:

Debt-to-Equity Ratio: 0.41%
Current Ratio: 2.07%
Quick Ratio: 1.94%

Additional Links:

Companies Related to BioTelemetry:

Consensus Ratings for BioTelemetry (NASDAQ:BEAT) (?)

Ratings Breakdown:	2 Buy Ratings
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$26.00 (39.94% upside)

Analysts' Ratings History for BioTelemetry (NASDAQ:BEAT)

Show:

Date	Firm	Action	Rating	Price Target
9/13/2016	Sidoti	Initiated Coverage	Buy	$27.00
8/3/2016	Benchmark Co.	Boost Price Target	Buy	$20.00 -> $25.00
7/28/2015	Dougherty & Co	Boost Price Target	Buy	$18.00 -> $20.00
11/24/2014	Avondale Partners	Upgrade	Market Perform -> Outperform

(Data available from 9/27/2014 forward)

Earnings History for BioTelemetry (NASDAQ:BEAT)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/7/2016
8/2/2016	Q2	$0.17	$0.20	$50.27 million	$52.68 million	View	Listen
4/26/2016	Q1	$0.10	$0.20	$46.54 million	$48.60 million	View	Listen
2/17/2016	Q415	$0.11	$0.15	$45.89 million	$46.70 million	View	Listen
11/9/2015	Q3	$0.11	$0.13	$46.05 million	$43.49 million	View	N/A
8/6/2015	Q2	$0.09	$0.12	$45.75 million	$44.81 million	View	Listen
5/6/2015	Q115	$0.02	$0.06	$43.80 million	$43.40 million	View	Listen
2/19/2015	Q414	$0.06	$0.05	$43.40 million	$43.70 million	View	Listen
10/30/2014	Q214	$0.02	$0.06	$42.00 million	$43.00 million	View	Listen
7/31/2014	Q114	$0.01	$0.02	$40.95 million	$42.70 million	View	Listen
5/6/2014	Q413	($0.02)	($0.04)	$38.40 million	$37.16 million	View	Listen
2/26/2014	Q313	($0.04)	$0.05	$32.26 million	$33.10 million	View	Listen
11/5/2013		($0.05)	($0.12)	$32.79 million	$31.90 million	View	Listen
7/30/2013	Q2 2013		$0.02	$27.50 million	$32.10 million	View	Listen
2/13/2013	Q4 2012		($0.09)	$26.80 million	$30.00 million	View	Listen
11/5/2012	Q312	($0.09)	($0.08)	$26.49 million	$27.00 million	View	N/A
8/8/2012		($0.04)	($0.01)			View	N/A
5/8/2012		($0.12)	($0.10)			View	N/A
2/22/2012		($0.13)	($0.04)			View	N/A
11/8/2011		($0.09)	($0.21)			View	N/A
8/8/2011		($0.06)	($0.05)			View	N/A
5/3/2011		($0.15)	($0.02)			View	N/A
2/17/2011		($0.16)	($0.13)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for BioTelemetry (NASDAQ:BEAT)

Current Year EPS Consensus Estimate: $0.75 EPS
Next Year EPS Consensus Estimate: $0.84 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	2	$0.08	$0.09	$0.09
Q2 2016	1	$0.16	$0.16	$0.16
Q3 2016	1	$0.18	$0.18	$0.18
Q4 2016	1	$0.20	$0.20	$0.20
Q1 2017	1	$0.21	$0.21	$0.21
Q2 2017	1	$0.20	$0.20	$0.20
Q3 2017	1	$0.20	$0.20	$0.20
Q4 2017	1	$0.22	$0.22	$0.22

(Data provided by Zacks Investment Research)

Dividend History for BioTelemetry (NASDAQ:BEAT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for BioTelemetry (NASDAQ:BEAT)

Insider Ownership Percentage: 11.00%
Institutional Ownership Percentage: 78.28%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/19/2016	George Hrenko	SVP	Sell	1,061	$18.50	$19,628.50
9/13/2016	Heather C Getz	CFO	Sell	5,866	$18.23	$106,937.18
9/13/2016	Joseph H Capper	Insider	Sell	26,847	$18.23	$489,420.81
9/13/2016	Peter Ferola	General Counsel	Sell	4,352	$18.23	$79,336.96
9/9/2016	Fred Broadway	SVP	Sell	3,146	$17.84	$56,124.64
9/8/2016	George Hrenko	SVP	Sell	3,491	$18.06	$63,047.46
9/8/2016	Heather C Getz	CFO	Sell	2,979	$18.10	$53,919.90
9/8/2016	Joseph H Capper	Insider	Sell	13,632	$18.10	$246,739.20
9/8/2016	Peter Ferola	General Counsel	Sell	2,210	$18.10	$40,001.00
9/7/2016	Daniel Wisniewski	SVP	Sell	9,225	$18.51	$170,754.75
9/7/2016	Heather C Getz	CFO	Sell	18,945	$18.52	$350,861.40
9/7/2016	Joseph H Capper	Insider	Sell	86,681	$18.52	$1,605,332.12
9/7/2016	Peter Ferola	General Counsel	Sell	14,053	$18.52	$260,261.56
9/6/2016	Fred Broadway	SVP	Sell	4,662	$18.28	$85,221.36
9/6/2016	Heather C Getz	CFO	Sell	6,686	$18.29	$122,286.94
9/6/2016	Joseph H Capper	CEO	Sell	30,595	$18.29	$559,582.55
9/6/2016	Peter Ferola	General Counsel	Sell	4,960	$18.29	$90,718.40
9/2/2016	Fred Broadway	SVP	Sell	4,466	$18.75	$83,737.50
9/2/2016	Heather C Getz	CFO	Sell	6,547	$18.75	$122,756.25
9/2/2016	Joseph H Capper	CEO	Sell	29,953	$18.75	$561,618.75
9/2/2016	Peter Ferola	General Counsel	Sell	4,856	$18.75	$91,050.00
9/1/2016	Fred Broadway	SVP	Sell	7,525	$19.25	$144,856.25
9/1/2016	Heather C Getz	CFO	Sell	10,408	$18.59	$193,484.72
9/1/2016	Joseph H Capper	Insider	Sell	47,622	$18.59	$885,292.98
9/1/2016	Peter Ferola	General Counsel	Sell	7,722	$18.59	$143,551.98
8/30/2016	Fred Broadway	SVP	Sell	12,121	$19.07	$231,147.47
8/30/2016	Heather C Getz	CFO	Sell	17,482	$19.07	$333,381.74
8/30/2016	Joseph H Capper	Insider	Sell	79,986	$19.07	$1,525,333.02
8/30/2016	Peter Ferola	General Counsel	Sell	12,970	$19.07	$247,337.90
8/25/2016	Fred Broadway	SVP	Sell	5,877	$19.16	$112,603.32
8/25/2016	Heather C Getz	CFO	Sell	8,477	$19.16	$162,419.32
8/25/2016	Joseph H Capper	Insider	Sell	38,785	$19.16	$743,120.60
8/25/2016	Peter Ferola	General Counsel	Sell	6,289	$19.16	$120,497.24
8/24/2016	George Hrenko	SVP	Sell	7,473	$20.11	$150,282.03
8/24/2016	Heather C Getz	CFO	Sell	8,778	$20.11	$176,525.58
8/24/2016	Joseph H Capper	CEO	Sell	40,160	$20.11	$807,617.60
8/24/2016	Peter Ferola	General Counsel	Sell	6,512	$20.11	$130,956.32
8/23/2016	George Hrenko	SVP	Sell	3,165	$20.67	$65,420.55
8/23/2016	Heather C Getz	CFO	Sell	3,717	$20.67	$76,830.39
8/23/2016	Joseph H Capper	CEO	Sell	17,008	$20.67	$351,555.36
8/23/2016	Peter Ferola	General Counsel	Sell	2,758	$20.67	$57,007.86
8/22/2016	George Hrenko	SVP	Sell	4,149	$20.85	$86,506.65
8/22/2016	Heather C Getz	CFO	Sell	4,874	$20.85	$101,622.90
8/22/2016	Joseph H Capper	CEO	Sell	22,298	$20.85	$464,913.30
8/22/2016	Peter Ferola	General Counsel	Sell	3,616	$20.85	$75,393.60
8/19/2016	Daniel Wisniewski	SVP	Sell	9,025	$20.96	$189,164.00
8/19/2016	Heather C Getz	CFO	Sell	9,026	$20.96	$189,184.96
8/19/2016	Joseph H Capper	Insider	Sell	9,049	$20.96	$189,667.04
8/19/2016	Peter Ferola	General Counsel	Sell	9,035	$20.96	$189,373.60
5/9/2014	Ronald Ahrens	Director	Buy	6,000	$7.37	$44,220.00
11/12/2013	Ronald Ahrens	Director	Buy	5,000	$11.73	$58,650.00
11/12/2012	Ronald A Ahrens	Director	Buy	15,000	$2.22	$33,300.00
9/5/2012	Joseph H Capper	CEO	Buy	23,540	$2.25	$52,965.00
8/31/2012	Joseph H Capper	CEO	Buy	2,600	$2.28	$5,928.00
8/29/2012	Joseph H Capper	CEO	Buy	10,800	$2.30	$24,840.00
8/28/2012	Joseph H Capper	CEO	Buy	1,300	$2.19	$2,847.00
8/27/2012	Joseph H Capper	CEO	Buy	1,600	$2.12	$3,392.00
8/23/2012	Joseph H Capper	CEO	Buy	9,600	$2.08	$19,968.00
8/20/2012	Joseph H Capper	CEO	Buy	14,160	$1.97	$27,895.20
8/17/2012	Joseph H Capper	CEO	Buy	9,800	$2.10	$20,580.00

(Data available from 1/1/2013 forward)

Latest Headlines for BioTelemetry (NASDAQ:BEAT)

Date	Headline
	Former Exec Files $15.5M Fraud Suit Against BioTelemetry, Inc (NASDAQ:BEAT) www.prlog.org - September 22 at 9:38 AM
	BioTelemetry, Inc. – Value Analysis (NASDAQ:BEAT) : September 19, 2016 (NASDAQ:BEAT) www.capitalcube.com - September 19 at 4:43 PM
	BioTelemetry, Inc. breached its 50 day moving average in a Bullish Manner : BEAT-US : September 16, 2016 (NASDAQ:BEAT) www.capitalcube.com - September 16 at 3:47 PM
	BioTelemetry, Inc. breached its 50 day moving average in a Bullish Manner : BEAT-US : September 16, 2016 (NASDAQ:BEAT) www.capitalcube.com - September 16 at 3:47 PM
	Shark Bites: Putting Cash to Work Isn't Easy (NASDAQ:BEAT) realmoney.thestreet.com - September 15 at 4:17 PM
	Coverage initiated on BioTelemetry by Sidoti (NASDAQ:BEAT) finance.yahoo.com - September 13 at 4:56 PM
	Shares Slipping Lower Over the Past Month: BioTelemetry, Inc. (NASDAQ:BEAT) - Post News (NASDAQ:BEAT) www.kentuckypostnews.com - September 1 at 3:45 PM
	BioTelemetry, Inc. breached its 50 day moving average in a Bearish Manner : BEAT-US : September 1, 2016 (NASDAQ:BEAT) www.capitalcube.com - September 1 at 12:13 PM
	BioTelemetry, Inc. announces CE mark approval of Holter analysis software - GlobeNewswire (press release) (NASDAQ:BEAT) globenewswire.com - August 30 at 3:45 PM
	BioTelemetry : announces CE mark approval of Holter analysis software (NASDAQ:BEAT) www.4-traders.com - August 30 at 8:47 AM
	BioTelemetry's (BEAT) Holter Analysis Software Receives CE Mark (NASDAQ:BEAT) www.streetinsider.com - August 29 at 9:27 PM
	BioTelemetry, Inc. announces CE mark approval of Holter analysis software (NASDAQ:BEAT) www.publicnow.com - August 29 at 4:24 PM
	BioTelemetry, Vonage and TPI Composites Have Dipped (NASDAQ:BEAT) realmoney.thestreet.com - August 25 at 3:50 PM
	Shark Bites: BioTelemetry, Vonage and TPI Composites Have Dipped (NASDAQ:BEAT) realmoney.thestreet.com - August 25 at 3:50 PM
	BioTelemetry (BEAT) to License Technology to Bloomlife (NASDAQ:BEAT) www.streetinsider.com - August 23 at 9:01 PM
	BIOTELEMETRY, INC. Files SEC form 8-K, Other Events (NASDAQ:BEAT) biz.yahoo.com - August 23 at 9:01 PM
	BioTelemetry, Inc. Agrees to License Proprietary Technology to Bloom Technologies, Inc. for Use in Prenatal Market - GlobeNewswire (press release) (NASDAQ:BEAT) globenewswire.com - August 23 at 3:49 PM
	8:16 am BioTelemetry enters a strategic partnership with Bloom Technologies (NASDAQ:BEAT) finance.yahoo.com - August 23 at 3:49 PM
	BioTelemetry, Inc. Agrees to License Proprietary Technology to Bloom Technologies, Inc. for Use in Prenatal Market (NASDAQ:BEAT) www.publicnow.com - August 23 at 3:49 PM
	HC Stocks Alerts: BioTelemetry, Inc. (NASDAQ:BEAT) Tokai ... - share market updates (press release) (NASDAQ:BEAT) sharemarketupdates.com - August 22 at 3:50 PM
	Will BioTelemetry, Inc. (NASDAQ:BEAT) Hit $25 Price Target? - Investor Newswire (NASDAQ:BEAT) www.investornewswire.com - August 20 at 3:48 PM
	Why BioTelemetry (BEAT) Could Be Positioned for a Surge? (NASDAQ:BEAT) finance.yahoo.com - August 18 at 12:12 PM
	Edited Transcript of BEAT earnings conference call or presentation 2-Aug-16 9:00pm GMT (NASDAQ:BEAT) finance.yahoo.com - August 16 at 12:31 PM
	BIOTELEMETRY, INC. Financials (NASDAQ:BEAT) finance.yahoo.com - August 11 at 3:53 PM
	BioTelemetry, Inc. :BEAT-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:BEAT) www.capitalcube.com - August 10 at 4:10 PM
	Is BioTelemetry (BEAT) Stock a Solid Choice Right Now? (NASDAQ:BEAT) www.nasdaq.com - August 9 at 4:57 PM
	Analysts Remain Strong on BioTelemetry, Inc. (NASDAQ:BEAT ... - Duncan News (NASDAQ:BEAT) www.duncanindependent.com - August 6 at 4:11 PM
	Analysts Update on Stocks: Endo International plc (NASDAQ:ENDP) , BioTelemetry, Inc. (NASDAQ:BEAT) - Street Updates (NASDAQ:BEAT) www.streetupdates.com - August 4 at 3:54 PM
	BioTelemetry Inc. (BEAT) Jumps 6.31% on August 03 - Equities.com (NASDAQ:BEAT) www.equities.com - August 4 at 12:23 PM
	BIOTELEMETRY, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:BEAT) biz.yahoo.com - August 3 at 9:28 PM
	Notable movements of Stocks: BioTelemetry, Inc. (NASDAQ:BEAT) , NxStage Medical, Inc. (NASDAQ:NXTM) - Street Updates (NASDAQ:BEAT) www.streetupdates.com - August 3 at 3:50 PM
	BioTelemetry Inc. : BioTelemetry, Inc. Reports Second Quarter 2016 Financial Results (NASDAQ:BEAT) www.twst.com - August 2 at 9:27 PM
	BioTelemetry posts 2Q profit (NASDAQ:BEAT) sg.finance.yahoo.com - August 2 at 9:27 PM
	Earnings Reaction History: BioTelemetry, Inc., 66.7% Follow-Through - Nasdaq (NASDAQ:BEAT) www.nasdaq.com - August 2 at 3:47 PM
	Q2 2016 BioTelemetry Inc Earnings Release - After Market Close (NASDAQ:BEAT) biz.yahoo.com - August 2 at 8:35 AM
	Recent Analysts Ratings of Stocks: BioTelemetry, Inc. (NASDAQ:BEAT) , Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Street Updates (NASDAQ:BEAT) www.streetupdates.com - August 1 at 8:44 AM
	HC Stocks Alerts: BioTelemetry, Inc. (NASDAQ:BEAT) Tokai Pharmaceuticals Inc (NASDAQ:TKAI) - share market updates (press release) (NASDAQ:BEAT) sharemarketupdates.com - August 1 at 8:44 AM
	BioTelemetry, Inc. (NASDAQ:BEAT) Updated Price Targets - FTSE News (NASDAQ:BEAT) www.ftsenews.co.uk - July 29 at 3:50 PM
	BioTelemetry Inc. (BEAT) Hits New 52-week High During July 26 Session - Equities.com (NASDAQ:BEAT) www.equities.com - July 29 at 7:58 AM
	BioTelemetry : Announces FDA Approval of Its Next Generation Device, the MCOT Patch (NASDAQ:BEAT) www.4-traders.com - July 27 at 9:34 PM
	Analysts Tips to Monitor: Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) , BioTelemetry, Inc. (NASDAQ:BEAT) - Street Updates (NASDAQ:BEAT) www.streetupdates.com - July 27 at 3:49 PM
	BioTelemetry's (BEAT) MCOT Patch Approved by U.S. FDA (NASDAQ:BEAT) www.streetinsider.com - July 27 at 12:19 PM
	BioTelemetry Inc (BEAT) Gets FDA Approval, Shares Move Up With Trading Volume - BNB Daily (blog) (NASDAQ:BEAT) www.baseball-news-blog.com - July 26 at 9:48 PM
	BioTelemetry Inc. (BEAT) Jumps 7.79% on July 26 - Equities.com (NASDAQ:BEAT) www.equities.com - July 26 at 9:48 PM
	BioTelemetry, Inc. to Release Second Quarter 2016 Earnings Results on August 2, 2016 (NASDAQ:BEAT) www.publicnow.com - July 26 at 4:38 PM
	BioTelemetry, Inc. Announces FDA Approval of Its Next Generation Device, the MCOT™ Patch - GlobeNewswire (press release) (NASDAQ:BEAT) globenewswire.com - July 26 at 3:41 PM
	BioTelemetry, Inc. Announces FDA Approval of Its Next Generation Device, the MCOT™ Patch (NASDAQ:BEAT) globenewswire.com - July 26 at 11:27 AM
	BioTelemetry Gets FDA Clearance For Its MCOT Patch (NASDAQ:BEAT) finance.yahoo.com - July 26 at 10:03 AM
	Is $19 Price Target Attainable For BioTelemetry, Inc. (NASDAQ:BEAT)? - Investor Newswire (NASDAQ:BEAT) www.investornewswire.com - July 24 at 8:30 AM
	BioTelemetry Inc. (BEAT) Hits New 52-week High During July 21 Session - Equities.com (NASDAQ:BEAT) www.equities.com - July 23 at 8:00 AM